Modality
Radioligand
MOA
HPK1i
Target
CD20
Pathway
Proteasome
Ovarian CaAlzheimer'sEpilepsy
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
~Aug 2021
→ ~Nov 2022
Phase 2
Feb 2023
→ Apr 2028
Phase 2Current
NCT08876190
2,001 pts·Ovarian Ca
2023-02→2028-04·Terminated
2,001 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-082.0y awayPh2 Data· Ovarian Ca
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2
Termina…
Catalysts
Ph2 Data
2028-04-08 · 2.0y away
Ovarian Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08876190 | Phase 2 | Ovarian Ca | Terminated | 2001 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 |